EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions

Patrick P Carriere, Comron J Hassanzadeh

Journal of Clinical Medicine · 30.06.2026 · 15 (13) · 5101

DOI: 10.3390/jcm15135101 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.06.2026. Verfasst von Patrick P Carriere und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd…. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder preservation has emerged as an established treatment option for selected patients with muscle-invasive bladder cancer (MIBC), offering durable oncologic control with the potential to maintain native bladder function and quality of life. Over the past several decades, prospective trials and large institutional experiences have refined trimodality therapy (TMT)—maximal transurethral resection followed by definitive radiation therapy with concurrent radiosensitizing systemic therapy—and clarified principles of patient selection, treatment delivery, surveillance, and salvage. Randomized evidence supports combined-modality therapy as the backbone of bladder preservation, and contemporary comparative analyses suggest outcomes comparable to radical cystectomy in appropriately selected populations. This review synthesizes the clinical foundations of bladder preservation, including radiobiologic considerations, advances in radiation technique, and patterns of recurrence following TMT. We discuss outcomes in higher-risk populations, including locally advanced and node-positive disease, and examine the evolving integration of systemic therapies. The emergence of immune checkpoint inhibitors and antibody–drug conjugates in urothelial carcinoma has reshaped the systemic treatment landscape and raises important questions regarding patient selection, sequencing, and the potential expansion of organ-preserving strategies. Finally, we outline future directions—including response-adaptive approaches, advances in image-guided and adaptive radiotherapy, and ctDNA-enabled risk stratification—while emphasizing the need for prospective validation and multidisciplinary collaboration to refine and optimize bladder-preserving care.

Schlagwörter

Stichwörter der Autor:innen

bladder preservationmuscle-invasive bladder cancerradiation therapytrimodality therapy

Autor:innen und Institutionen

  • Division of Radiation Oncology, Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Zitieren

APA

Carriere, P. P., & Hassanzadeh, C. J. (2026). Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions. Journal of Clinical Medicine, 15(13), 5101. https://doi.org/10.3390/jcm15135101

Vancouver

Carriere PP, Hassanzadeh CJ. Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions. Journal of Clinical Medicine. 2026;15(13):5101. doi:10.3390/jcm15135101

BibTeX
@article{Carriere2026,
  author = {Carriere, Patrick P and Hassanzadeh, Comron J},
  title = {Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {5101},
  doi = {10.3390/jcm15135101}
}
Kostenlos starten →